Follow-up periods and required doses applied per vaccine for series completion.</p
Population fraction infected at the end of the simulation period (77 days) under varying vaccination...
The intensity of any local and systemic events within 30 minutes post-vaccination.</p
<p>The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and...
Completion status of vaccine series based on year of incident prescription, and number and proportio...
Administered doses by Apr 2, 2021 (end of follow-up time) of each vaccine and number of COVID-19 inf...
Percentage of pharmacists authorized to administer injections and percentage of series completion pe...
Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE w...
<p>Numbers of doses of vaccine delivered by various deployment strategies over time.</p
A. Anti-nucleocapsid antibody levels during follow-up. B. Median anti-spike antibody levels during f...
<p>Vaccination and Specimen Collection Schedule for both Group 1 and Group 2.</p
<p>Cohort enrolment, treatment and follow up and decision making for progression to screening of the...
Medications and devices applied during follow-up, after treatment optimization.</p
Frequency of antibody responses as determined by ELISA four weeks after the final vaccination.</p
Screening, enrollment, PK study, and one-year follow-up to assess drug efficacy.</p
<p>A chronology of events about the pH1N1vaccine availability, reporting of potential vaccine-relate...
Population fraction infected at the end of the simulation period (77 days) under varying vaccination...
The intensity of any local and systemic events within 30 minutes post-vaccination.</p
<p>The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and...
Completion status of vaccine series based on year of incident prescription, and number and proportio...
Administered doses by Apr 2, 2021 (end of follow-up time) of each vaccine and number of COVID-19 inf...
Percentage of pharmacists authorized to administer injections and percentage of series completion pe...
Number of vaccine doses administered and median interval of TBE occurrence in any patient with TBE w...
<p>Numbers of doses of vaccine delivered by various deployment strategies over time.</p
A. Anti-nucleocapsid antibody levels during follow-up. B. Median anti-spike antibody levels during f...
<p>Vaccination and Specimen Collection Schedule for both Group 1 and Group 2.</p
<p>Cohort enrolment, treatment and follow up and decision making for progression to screening of the...
Medications and devices applied during follow-up, after treatment optimization.</p
Frequency of antibody responses as determined by ELISA four weeks after the final vaccination.</p
Screening, enrollment, PK study, and one-year follow-up to assess drug efficacy.</p
<p>A chronology of events about the pH1N1vaccine availability, reporting of potential vaccine-relate...
Population fraction infected at the end of the simulation period (77 days) under varying vaccination...
The intensity of any local and systemic events within 30 minutes post-vaccination.</p
<p>The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and...
DOI
Add to ORKG